Publications

Recent Approvals of Medicines Containing a New Active Ingredient

This article is more than five years old. Some content may no longer be current.

Prescriber Update 38(3): 44
September 2017

For period 16 April 2017 to 15 July 2017

Trade Name (active ingredient)*	Dose form and strength	Therapeutic area
Akynzeo (netupitant/palonosetron)^†	Combination capsule 300 mg/0.5 mg	Chemotherapy-induced nausea and vomiting
Ibrance (palbociclib)	Capsule 75 mg, 100 mg and 125 mg	Hormone-receptor positive, HER2-negative, advanced breast cancer
Idelvion (albutrepenonacog alfa)	Powder for injection 250 IU, 500 IU, 1000 IU and 2000 IU	Haemophilia B
Nucala (mepolizumab)	Powder for injection 100 mg/mL	Eosinophilic asthma
Ranexa (ranolazine)	Modified release tablet 375 mg, 500 mg and 750 mg	Angina

* New active ingredient shown in bold type^† Not available

The data sheets for currently marketed prescription medicines are published on the Medsafe website (www.medsafe.govt.nz/profs/Medicines/infoSearch.asp).